83,135 Shares in Indivior PLC $INDV Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA bought a new position in Indivior PLC (NASDAQ:INDV) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 83,135 shares of the company’s stock, valued at approximately $2,983,000.

A number of other institutional investors have also added to or reduced their stakes in INDV. CWM LLC bought a new position in Indivior in the 3rd quarter worth about $25,000. Quarry LP bought a new position in Indivior in the 3rd quarter worth about $26,000. Raymond James Financial Inc. bought a new position in Indivior in the 2nd quarter worth about $26,000. Harbor Capital Advisors Inc. increased its stake in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after acquiring an additional 781 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Insider Transactions at Indivior

In related news, Director Stuart A. Kingsley bought 940 shares of the business’s stock in a transaction on Friday, March 6th. The shares were bought at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the purchase, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This trade represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.74% of the stock is owned by company insiders.

Indivior Stock Up 3.8%

Indivior stock opened at $32.70 on Friday. The business has a fifty day moving average of $31.91 and a two-hundred day moving average of $31.77. The firm has a market cap of $3.99 billion, a P/E ratio of 19.94 and a beta of 0.88. Indivior PLC has a twelve month low of $8.69 and a twelve month high of $38.00.

Indivior (NASDAQ:INDV) last posted its earnings results on Friday, February 27th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million for the quarter, compared to analyst estimates of $305.62 million. Equities analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on INDV shares. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Finally, HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Indivior presently has an average rating of “Buy” and a consensus target price of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.